On This Day in Health: March 8, 2024
On March 8, 2024, the United States Food and Drug Administration approved a new indication for Wegovy, the injectable form of semaglutide used for weight management. The expanded authorization concerned reducing the risk of cardiovascular death, heart attack, and stroke in adults who already had cardiovascular disease and also had obesity or overweight. It did not create a universal heart-disease indication for everyone taking the medicine. The decision connected the treatment of body weight with evidence about major cardiovascular outcomes, giving the drug a role defined by both a patient's existing disease and the results of a large clinical trial.
Semaglutide belongs to the glucagon-like peptide-1 receptor agonist class, usually shortened to GLP-1. Wegovy had already been authorized for weight management before the March 2024 expansion. The new decision depended on evidence that went beyond a change on a scale: researchers examined whether treatment affected serious events involving the heart and blood vessels. That distinction matters because a medicine can influence a risk factor without necessarily proving that it changes the outcomes people most want to avoid. A trial designed around cardiovascular events could address that separate question directly. The resulting indication described a particular population in whom such evidence had been established.
The SELECT trial enrolled more than 17,600 participants with established cardiovascular disease, overweight or obesity, and no history of diabetes. They were assigned to semaglutide or placebo while continuing standard cardiovascular care. The main composite outcome occurred in 6.5 percent of participants receiving the drug and 8 percent receiving placebo. These group results supported the approval, but the medicine was not presented as a replacement for the rest of cardiovascular care. Management of blood pressure and cholesterol, together with dietary and activity counseling, remained part of the trial setting. Understanding what both groups received helps explain what the study actually compared and prevents the drug's contribution from being separated from its clinical context.
The expanded authorization also retained a prescribing framework addressing risks and patient suitability. It represented an additional use for an existing medicine, rather than proof that treatment was free of adverse effects or that every patient would avoid a future cardiovascular event. March 8 is significant because evidence from an outcomes trial became a defined regulatory indication. The broader history shows a shift in how a weight-management therapy could be assessed: not only through weight change, but also through serious health events over time. The decision linked two areas of care often discussed separately, while leaving the practical questions of access, monitoring, and individual treatment decisions to the health system and the clinical relationship in which the medicine would be used.
The new indication applied to adults with established cardiovascular disease and obesity or overweight. It was narrower than a general claim of heart protection.
Wegovy already had a weight-management authorization. March 8 marked an expansion based on cardiovascular outcomes rather than its first approval.
SELECT studied more than 17,600 participants without a history of diabetes. Both groups continued standard cardiovascular care.
The major composite event occurred in 6.5 percent of the treatment group and 8 percent of the placebo group. These were trial averages.
The medicine's contribution was evaluated alongside existing care. Blood pressure and cholesterol management formed part of that context.
An outcomes-based indication connects risk-factor treatment with measured health events. It still requires decisions about suitability and practical access.
Explore more of "On This Day ..."
Discover more events from the same date across news, politics, technology, sports, and other fields. Each link highlights significant moments that shaped history on different fronts.